Posts

The Peptide Knowledge Hub: Evidence, Benefits, Risks and Safety (2026 Guide)

Image
OneDayMD Research Team | Evidence and regulatory review: 16 November 2026 | Independent health research and education Peptides have become one of the most talked-about subjects in modern medicine, regenerative medicine, aesthetics, sports performance and longevity research. From GLP-1 medications for obesity and diabetes to BPC-157 for tissue repair, GHK-Cu for skin health and MOTS-c for metabolic research, interest in peptides is expanding rapidly. But an important question is often overlooked: what do we actually know about these substances, and how much of what is being marketed has been demonstrated in humans? Some peptide-based medicines have transformed clinical care and are supported by extensive randomised controlled trials. Other compounds have demonstrated interesting biological effects in laboratory experiments or animal models but have little or no reliable human evidence. The rapidly growing market has also created concerns about product authenticity, m...

GLP-1 Hub 2026: Approved Drugs, Pills vs Injections, Retatrutide & Safety

Image
Home › GLP-1 Hub By Dr. Frank Yap, MD  |  Last updated: November 2026  |  Purpose: evidence and safety education, not individual medical advice Quick Answer GLP-1 therapy now includes injections and, since 2025–2026, two FDA-approved pills : oral Wegovy (semaglutide 25 mg, December 2025) and Foundayo (orforglipron) , approved April 1, 2026 as the first non-peptide oral GLP-1 for weight management.  The 5 November 2026 Science special issue (“GLP-1 and Beyond”) examines how GLP-1 receptor agonists and related metabolism-targeting drugs affect systems beyond classic metabolic disease—especially the brain—while highlighting the shift toward multi-receptor agents. Retatrutide is not approved anywhere ; it remains in Phase 3 testing. Compounded and gray-market GLP-1 or peptide products are not FDA-approved, and the FDA issued warning letters to telehealth compounders in March 2026. Any GLP-1 plan should run through a licensed physician and a regu...